Crestor Generics To Launch After 12-Day Delay

AstraZeneca's legal gambit results in almost two more weeks of sales for the statin even though the court ultimately agreed with FDA on labeling carve-out for orphan indication.

court house

AstraZeneca Pharmaceuticals LP struck out in its attempt to use a new pediatric orphan indication for Crestor (rosuvastatin) to block generic competition for seven more years. But the company was able to delay the launch of generic versions of the cholesterol-lowering blockbuster for 12 days, garnering it tens of millions of dollars in revenue.

On July 19, Judge Randolph Moss, of the U.S. District Court for the District of Columbia, denied AstraZeneca's motion for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Pink Sheet

National Priority Voucher Gives US FDA Commissioner Tool For Radical Regulatory Surgery

 

US FDA Commissioner Martin Makary will establish "national priorities" used to select sponsors for the pilot of “tumor board-style” drug reviews that would start before Phase III is completed.

US FDA’s CoGenT Pilot At Risk? Project Orbis Success May Not Save Cell/Gene Therapy Initiative

 

Despite following the path of the popular Project Orbis, the cell and gene therapy international collaborative review pilot is being reconsidered by the FDA's new management.

HTA Expert Warns Of Escalating Measures If Pharma Fails To Tame Prices

 

Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.